Market Research News

Scleroderma (Systemic Sclerosis) Treatment Market 2019 Global Trend, CAGR Status, Growth, Analysis and Forecast to 2026

Global Scleroderma (Systemic Sclerosis) Treatment Market, By Type (Limited, Diffuse), By Therapeutics (Immunosuppressant, Calcium-Channel Blockers, Endothelin Receptor Antagonists, PDE-5 Inhibitors, Prostacyclin Analogues, ACE Inhibitors), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends & Forecast to 2026

Request for FREE Sample Copy of This Report @

Key Market Competitors: 

  • Actelion Pharmaceuticals Ltd,
  • Hoffmann-La Roche Ltd,
  • Bristol-Myers Squibb Company,
  • Boehringer Ingelheim International GmbH,
  • GlaxoSmithKline plc.,
  • Biogen,
  • Novartis AG,
  • Teva Pharmaceutical Industries Ltd.,
  • AstraZeneca,
  • Asta Pharma,
  • Aspen Holdings,
  • A.C. PHARMA,
  • Pfizer Inc.,
  • Eli Lilly and Company,
  • Bayer AG,
  • Argentis Pharmaceuticals LLC.,
  • Amgen Inc.,
  • Corbus Pharmaceuticals Holdings Inc.,
  • Sanofi,
  • Cumberland Pharmaceuticals

Market Analysis: Global Scleroderma (Systemic Sclerosis) Treatment Market

With increased healthcare infrastructure, the need for disease-modifying therapies for systemic sclerosis has increased. This has induced the global scleroderma (systemic sclerosis) treatment market to grow considerably during the forecast period of 2019 to 2026. The upcoming market report contains data for historic years 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Definition: Global Scleroderma (Systemic Sclerosis) Treatment Market

Systemic sclerosis is a chronic autoimmune disorder characterized by the skin hardening, inflammation in multiple organs; the most common characteristic is thickening of skin in this disease. The exact cause of the disease is unknown but it is known to have an overproduction of collagen in the body. The disease is associated with high rates of mortality and lack of any therapeutics for the disease is affecting the market growth. Due to the disease’s effects on multiple organs, the treatments available are for the different affected areas and not the disease itself.

Market Drivers:

  • Increased investment in research & development for the development of treatment for systemic sclerosis is expected to drive the market growth
  • Rise in number of government initiatives and programs for the awareness of the disease and treatment options available is also expected to drive the market growth

Market Restraints:

  • Lack of a particular treatment for the disease and only options available for the symptoms of the disease is expected to act as a restraint to the market growth
  • Diagnosis and cause of the disease are still unknown which makes the selection of drugs for symptoms reliefs even more difficult for doctors as every case of scleroderma is different, this trend is expected to act as a restraint for the market growth

Inquiry Before Buying @

Segmentation: Global Scleroderma (Systemic Sclerosis) Treatment Market

By Type

  • Limited
  • Diffuse

By Therapeutics

  • Immunosuppressant
  • Calcium-Channel Blockers
  • Endothelin Receptor Antagonists
  • PDE-5 Inhibitors
  • Prostacyclin Analogues
  • ACE Inhibitors

By Geography

  • North America
  • US
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Turkey
  • Belgium
  • Netherlands
  • Switzerland
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • South Korea
  • India
  • Australia
  • Singapore
  • Malaysia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of Asia-Pacific
  • Middle East and Africa
  • South Africa
  • Egypt
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Rest of Middle East and Africa

Key Developments in the Market:

  • In September, 2016 European Medicines Agency and US Food and Drug Administration granted Boehringer Ingelheim International GmbH’s Ofev drug Orphan Drug Designation for the treatment of systemic sclerosis
  • In July, 2018 Combined Response Index for Systemic Sclerosis was presented at the European Congress of Rheumatology, which was presented to determine the effects of drugs in patients with systemic sclerosis.

Competitive Analysis: 

The global scleroderma (systemic sclerosis) treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of scleroderma (systemic sclerosis) treatment market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Get Detailed TOC @


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *